<DOC>
	<DOCNO>NCT01758185</DOCNO>
	<brief_summary>The objective study evaluate safety immunogenicity one inactivate split influenza vaccine , primarily Chinese-marketed trivalent vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Study Aleph Inactivated Split Influenza Vaccine</brief_title>
	<detailed_description>A total 3308 subject stratify equally four age group receive either influenza vaccine recombinant hepatitis b vaccine ( see placebo ) . Systematic local adverse reaction report 28 vaccination . Antibody level detect hemagglutination inhibition assay vaccination ( Baseline ) 28d vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>three year good healthy current infectious fever acute disease upper respiratory infectious symptom within 6m history allergy laboratory confirm influenza autoimmune disease get influenza vaccine since 2008</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Inactivated split influenza vaccine</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Consistence</keyword>
</DOC>